These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States. Sipp D Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146 [TBL] [Abstract][Full Text] [Related]
3. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Turner L Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145 [TBL] [Abstract][Full Text] [Related]
5. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions. Turner LG Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761 [No Abstract] [Full Text] [Related]
6. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents. Turner LG Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934 [No Abstract] [Full Text] [Related]
7. Rejuvenating Regenerative Medicine Regulation. Charo RA; Sipp D N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637 [No Abstract] [Full Text] [Related]
9. Identity and ownership issues in the regulation of autologous cells. Sipp D Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180 [TBL] [Abstract][Full Text] [Related]
10. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Turner L; Knoepfler P Cell Stem Cell; 2016 Aug; 19(2):154-157. PubMed ID: 27374789 [TBL] [Abstract][Full Text] [Related]
15. Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects. Liras A J Transl Med; 2010 Dec; 8():131. PubMed ID: 21143967 [TBL] [Abstract][Full Text] [Related]
16. Stem Cell Businesses and Right to Try Laws. Sipp D; Turner L; Rasko JEJ Cell Stem Cell; 2019 Sep; 25(3):304-305. PubMed ID: 31491393 [No Abstract] [Full Text] [Related]
17. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia. McLean AK; Stewart C; Kerridge I Stem Cell Res Ther; 2015 Feb; 6(1):33. PubMed ID: 25689404 [TBL] [Abstract][Full Text] [Related]
18. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era. Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106 [TBL] [Abstract][Full Text] [Related]
19. The dangers of unregulated stem-cell marketing. Mohammadi D Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714 [No Abstract] [Full Text] [Related]
20. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union. Pellegrini G; Ardigò D; Milazzo G; Iotti G; Guatelli P; Pelosi D; De Luca M Stem Cells Transl Med; 2018 Jan; 7(1):146-154. PubMed ID: 29280318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]